Log in

Harpoon Therapeutics Stock Price, Forecast & Analysis (NASDAQ:HARP)

$13.15
-0.10 (-0.75 %)
(As of 11/13/2019 01:54 AM ET)
Today's Range
$13.02
Now: $13.15
$13.43
50-Day Range
$12.93
MA: $13.63
$14.89
52-Week Range
$9.07
Now: $13.15
$17.85
Volume13,200 shs
Average Volume42,769 shs
Market Capitalization$323.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
Phone650-443-7400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.75 million

Profitability

Net Income$-27,370,000.00
Net Margins-1,107.97%

Miscellaneous

Employees45
Market Cap$323.99 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.


Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics Inc (NASDAQ:HARP) released its quarterly earnings results on Monday, August, 5th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.14. The company earned $1.06 million during the quarter, compared to analysts' expectations of $1.22 million. Harpoon Therapeutics had a negative return on equity of 86.88% and a negative net margin of 1,107.97%. View Harpoon Therapeutics' Earnings History.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Harpoon Therapeutics.

What price target have analysts set for HARP?

5 Wall Street analysts have issued 1-year price targets for Harpoon Therapeutics' stock. Their forecasts range from $22.00 to $25.00. On average, they anticipate Harpoon Therapeutics' share price to reach $23.25 in the next twelve months. This suggests a possible upside of 76.8% from the stock's current price. View Analyst Price Targets for Harpoon Therapeutics.

What is the consensus analysts' recommendation for Harpoon Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harpoon Therapeutics.

Has Harpoon Therapeutics been receiving favorable news coverage?

News articles about HARP stock have trended very negative this week, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Harpoon Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Harpoon Therapeutics.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 191,300 shares, a decline of 15.9% from the September 30th total of 227,400 shares. Based on an average daily volume of 50,800 shares, the days-to-cover ratio is currently 3.8 days. Approximately 1.5% of the shares of the stock are sold short. View Harpoon Therapeutics' Current Options Chain.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Universal Display (OLED), Alector (ALEC), Cisco Systems (CSCO), Intel (INTC), Shopify (SHOP), Advanced Micro Devices (AMD), Appian (APPN), Activision Blizzard (ATVI), Cara Therapeutics (CARA) and Codexis (CDXS).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the folowing people:
  • Dr. Luke B. Evnin, Chairman (Age 56)
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (0.01%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Gerald Phd Mcmahon, Luke Evnin and Natalie Sacks. View Institutional Ownership Trends for Harpoon Therapeutics.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was bought by a variety of institutional investors in the last quarter, including Tower Research Capital LLC TRC . Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Gerald Phd Mcmahon and Luke Evnin. View Insider Buying and Selling for Harpoon Therapeutics.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $13.15.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $323.99 million and generates $4.75 million in revenue each year. The company earns $-27,370,000.00 in net income (profit) each year or ($25.65) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.View Additional Information About Harpoon Therapeutics.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is http://www.harpoontx.com/.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]


MarketBeat Community Rating for Harpoon Therapeutics (NASDAQ HARP)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote "Outperform" if you believe HARP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel